Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights

– Net revenue rose 27% from prior quarter to $74.6 million –– CIMERLI® net sales increased 50% to $40 million compared to prior quarter –– LOQTORZI™ now approved with launch planned for...

Related Keywords

Junshi Biosciences ,Jami Taylor ,Jodi Sievers ,Coherus Biosciences ,Denny Lanfear ,Meeting Of Society ,Amgen Inc ,Drug Administration ,Surface Oncology Inc ,International Conference On Molecular ,Abbvie Inc ,Exchange Commission On ,Corporate Communications ,Coherus Biosciences Inc ,Exchange Commission ,Nasdaq ,Genentech Inc ,Medicare Advantage ,Biologics License Application ,Response Letter ,Molecular Targets ,Cancer Therapeutics ,Annual Meeting ,Oncology Acquisition ,Novel Immuno Oncology ,Surface Oncology ,Investigational New Drug ,Coheru Chairman ,Chief Executive ,On Body Injector ,Forward Looking Statements ,Private Securities Litigation Reform Act ,Coheru Quarterly Report ,Contact Information ,Consolidated Statements ,Stockholder Deficit ,Public Offering ,Markets ,